FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090994501> ?p ?o ?g. }

• W3090994501 abstract "Background . This retrospective study aimed to characterize the long-term (>24 months) safety profile of zoledronic acid (ZA). We aimed to investigate whether long-term ZA treatment had greater benefits than short-term treatment in patients from southern China with advanced breast cancer (ABC) with bone metastasis. Patients and Methods . A total of 566 metastatic breast cancer cases were included and divided into two groups according to the duration of ZA treatment. The included patients had at least one lytic bone lesion and had no skeletal-related events (SREs) prior to ZA therapy. The primary endpoint was to analyze the safety and long-term adverse effects, which covered osteonecrosis of jaws (ONJ), renal impairment, and hearing impairment. The second objective was to determine the efficacy of long-term ZA treatment by the incidence of SREs. Results . Fifteen patients were diagnosed with ONJ (2.7%): nine in the short-term group (3.1%) and six in the long-term group (2.2%, <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mi>P</mml:mi></mml:math> = 0.606). Five cases (0.9%) had renal function impairment: two in the short-term group (0.7%) and four in the long-term group (1.1%, <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M2><mml:mi>P</mml:mi></mml:math> = 0.676). One patient (0.2%) in the long-term group had hearing impairment after 23 months of ZA treatment (0.4%, <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M3><mml:mi>P</mml:mi></mml:math> = 0.482). In total, 103 cases in the short-term group (35.2%) and 138 cases in long-term group (50.5%) developed SREs (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M4><mml:mi>P</mml:mi></mml:math> < 0.001). The mean annual SRE rate was 0.3 in the short-term group (range, 0–3.1) versus 0.2 in the long-term group (0–1.0, <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M5><mml:mi>P</mml:mi></mml:math> = 0.269). Subgroup analysis suggested that cases with non-load-bearing bone involvement and those who received systematic anticancer therapy without chemotherapy might benefit from long-term ZA treatment. Cox regression analysis indicated poor performance status, and nonvisceral organ involvement predicted high risk for SRE. Conclusions . The extension of ZA treatment did not increase the long-term adverse events and reduced the annual incidence of SREs beyond 24 months. Although longer treatment of ZA over 24 months appeared to be safe, further prospective investigation is required." @default.
• W3090994501 created "2020-10-08" @default.
• W3090994501 creator A5010050815 @default.
• W3090994501 creator A5010889142 @default.
• W3090994501 creator A5012285236 @default.
• W3090994501 creator A5018393057 @default.
• W3090994501 creator A5018964484 @default.
• W3090994501 creator A5031142965 @default.
• W3090994501 creator A5040621608 @default.
• W3090994501 creator A5050289410 @default.
• W3090994501 creator A5064937355 @default.
• W3090994501 creator A5068679033 @default.
• W3090994501 creator A5071441248 @default.
• W3090994501 creator A5075883325 @default.
• W3090994501 creator A5080256378 @default.
• W3090994501 creator A5082372753 @default.
• W3090994501 creator A5089520808 @default.
• W3090994501 date "2020-09-30" @default.
• W3090994501 modified "2023-10-15" @default.
• W3090994501 title "Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China" @default.
• W3090994501 cites W147675881 @default.
• W3090994501 cites W1520425169 @default.
• W3090994501 cites W1822646907 @default.
• W3090994501 cites W1847691375 @default.
• W3090994501 cites W1951349736 @default.
• W3090994501 cites W1988350136 @default.
• W3090994501 cites W1995487613 @default.
• W3090994501 cites W1995615104 @default.
• W3090994501 cites W1996589664 @default.
• W3090994501 cites W2016612963 @default.
• W3090994501 cites W2061202924 @default.
• W3090994501 cites W2070427768 @default.
• W3090994501 cites W2104923745 @default.
• W3090994501 cites W2107118598 @default.
• W3090994501 cites W2115871403 @default.
• W3090994501 cites W2122560580 @default.
• W3090994501 cites W2125035379 @default.
• W3090994501 cites W2126520912 @default.
• W3090994501 cites W2137083298 @default.
• W3090994501 cites W2137302084 @default.
• W3090994501 cites W2138220544 @default.
• W3090994501 cites W2139774670 @default.
• W3090994501 cites W2142234592 @default.
• W3090994501 cites W2152409486 @default.
• W3090994501 cites W2170309090 @default.
• W3090994501 cites W2290764327 @default.
• W3090994501 cites W2563302682 @default.
• W3090994501 cites W2576634613 @default.
• W3090994501 cites W2581286732 @default.
• W3090994501 cites W2765774285 @default.
• W3090994501 cites W2766547212 @default.
• W3090994501 cites W2769314721 @default.
• W3090994501 cites W4256653765 @default.
• W3090994501 doi "https://doi.org/10.1155/2020/5670601" @default.
• W3090994501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7545466" @default.
• W3090994501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33061970" @default.
• W3090994501 hasPublicationYear "2020" @default.
• W3090994501 type Work @default.
• W3090994501 sameAs 3090994501 @default.
• W3090994501 citedByCount "1" @default.
• W3090994501 countsByYear W30909945012022 @default.
• W3090994501 crossrefType "journal-article" @default.
• W3090994501 hasAuthorship W3090994501A5010050815 @default.
• W3090994501 hasAuthorship W3090994501A5010889142 @default.
• W3090994501 hasAuthorship W3090994501A5012285236 @default.
• W3090994501 hasAuthorship W3090994501A5018393057 @default.
• W3090994501 hasAuthorship W3090994501A5018964484 @default.
• W3090994501 hasAuthorship W3090994501A5031142965 @default.
• W3090994501 hasAuthorship W3090994501A5040621608 @default.
• W3090994501 hasAuthorship W3090994501A5050289410 @default.
• W3090994501 hasAuthorship W3090994501A5064937355 @default.
• W3090994501 hasAuthorship W3090994501A5068679033 @default.
• W3090994501 hasAuthorship W3090994501A5071441248 @default.
• W3090994501 hasAuthorship W3090994501A5075883325 @default.
• W3090994501 hasAuthorship W3090994501A5080256378 @default.
• W3090994501 hasAuthorship W3090994501A5082372753 @default.
• W3090994501 hasAuthorship W3090994501A5089520808 @default.
• W3090994501 hasBestOaLocation W30909945011 @default.
• W3090994501 hasConcept C11413529 @default.
• W3090994501 hasConcept C120665830 @default.
• W3090994501 hasConcept C121332964 @default.
• W3090994501 hasConcept C121608353 @default.
• W3090994501 hasConcept C126322002 @default.
• W3090994501 hasConcept C141071460 @default.
• W3090994501 hasConcept C143998085 @default.
• W3090994501 hasConcept C159641895 @default.
• W3090994501 hasConcept C197934379 @default.
• W3090994501 hasConcept C2776035513 @default.
• W3090994501 hasConcept C2776326535 @default.
• W3090994501 hasConcept C2776541429 @default.
• W3090994501 hasConcept C2777251235 @default.
• W3090994501 hasConcept C2777556957 @default.
• W3090994501 hasConcept C2777783956 @default.
• W3090994501 hasConcept C2779013556 @default.
• W3090994501 hasConcept C41008148 @default.
• W3090994501 hasConcept C530470458 @default.
• W3090994501 hasConcept C61511704 @default.
• W3090994501 hasConcept C71924100 @default.
• W3090994501 hasConceptScore W3090994501C11413529 @default.
• W3090994501 hasConceptScore W3090994501C120665830 @default.

• next